January 16, 2017 10:45 PM ET


Company Overview of Eli Lilly Canada Inc.

Company Overview

Eli Lilly Canada Inc. develops pharmaceutical products. It offers medicines to treat pulmonary arterial hypertension, erectile dysfunction, depression, diabetes, osteoporosis, cancer and other life-threatening and life-changing illnesses. The company was founded in 1938 and is based in Toronto, Canada with a regional office in Guelph, Canada. Eli Lilly Canada Inc. operates as a subsidiary of Eli Lilly and Company.

3650 Danforth Avenue

Toronto, ON M1N 2E8


Founded in 1938





Key Executives for Eli Lilly Canada Inc.

President and General Manager
Director of Communications
Compensation as of Fiscal Year 2016.

Eli Lilly Canada Inc. Key Developments

Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Announce Health Canada Approves JARDIANCE as an Adjunct to Diet and Exercise

Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada announced that Health Canada has approved JARDIANCE to be used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.1 JARDIANCE belongs to a new class of agents called sodium glucose co-transporter 2 (SGLT2) inhibitors that have a different mechanism of action from other oral glucose-lowering agents.2 JARDIANCE lowers the renal threshold for glucose, which leads to reduced renal reabsorption of filtered glucose and increased urinary glucose excretion.1.

Eli Lilly Canada Announces Introduction of Cyramza into Canada

Eli Lilly Canada announced that its new gastric cancer medicine, Cyramza, has been approved and is now available for use in Canada. Cyramza was authorized by Health Canada for use as a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression on or after prior platinum and fluoropyrimidine chemotherapy. In Canada, an estimated 3,400 new cases of gastric cancer are expected to be diagnosed in 2015, gastric cancer offers few discernible symptoms until the disease has reached an advanced stage 3,4. Consequently, patients are often diagnosed late in the progression of the disease, yielding poor outlooks for most patients. In Canada, the five year relative survival ratio is sixth-worst of all cancers, at approximately 25%. Cyramza is a human vascular endothelial growth factor receptor 2 antagonist and is administered as an IV solution by infusion. Clinical studies, including the RAINBOW and REGARD phase 3 trials, demonstrated Cyramza's efficacy and manageable side effect profile as a second-line therapy for gastric cancer 1,6,7.

Similar Private Companies By Industry

Company Name Region
4everPets Ltd. Americas
9037136 Canada Inc. Americas
AAA Heidelberg Inc. Americas
Ab Biotech Inc. Americas
AB Laboratories Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eli Lilly Canada Inc., please visit www.lilly.ca. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.